Aktienanalyse zu Ironwood Pharmaceuticals Inc (IRWD)IRWDIronwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ironwood Pharmaceuticals is not a good buy right now due to significant negative trends. The stock has dropped 19.72% over the last 20 days and has an RSI of 32.098, indicating it is oversold. Additionally, insider selling has surged by 22659.51%, which raises concerns about the company's future direction and stability.

11 analysts cover IRWD: 5 rate it Buy, 5 Hold and 1 Sell. The average price target is 6.23.